Brind.

Ocugen addressed unmet medical needs for Stargardt patients through recent announcements regarding their research in Europe.

1 report, 1 independent Updated Jul 21

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Ocugen Europe

How it developed

Newest first. Tap a step to see who reported it.

Jun 8Huma Qamar was appointed Chief Medical Officer at Ocugen.Sub-event
Jun 8Ocugen is updating its Retina Scientific Advisory Board, while Peter K Kaiser holds chairs at Cleveland Clinic and Ophthalmic Consultants of Boston.Sub-event
Jul 21Ocugen announced findings regarding unmet medical needs for Stargardt patients in Europe.1 source
- Clinical Trials Arena

Keep exploring

The entities involved

Ocugen
biopharmaceutical company

Nothing else this week.
Europe
terrestrial continent located in north-western Eurasia
- The European Commission aims to strengthen homegrown AI capabilities while global advanced models face usage restrictions.Mon 17:49
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49

Coverage

Newest first; wire copies grouped

Jul 21Clinical Trials ArenaOcugen doses first subject in trial of modifier gene therapy candidate Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST (AAV5-hRORA),